Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, Genmab Collaborate on Cancer Biomarker Discovery

NEW YORK – Genmab said today that it has entered into a strategic collaboration with Tempus to apply artificial intelligence to biomarker and target discovery in oncology.

Under the agreement, Copenhagen, Denmark-based Genmab will identify research projects for both companies to work on in pursuit of new drug targets and biomarkers. The partners will then will apply Tempus' sequencing and bioinformatics technology. Genmab will lead development and commercialization for any resulting products, though Tempus would be eligible for milestone and royalty payments. 

While financial terms were not disclosed, Chicago-based Tempus, a rapidly expanding sequencing and informatics company, has the option to fund part of any resulting product development programs with the promise of higher royalty payments, according to Genmab.

This deal represents an expansion of previous service agreements between the companies into a full-fledged collaboration.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.